ASH 2021

We are delighted to announce that 16 LYSA membres will be presenting their work on lymphoma studies during this meeting: 10 in oral communications and 6 posters.

 

The times below are for Atlanta (UTC−4)

 

Saturday, Dec. 11th

9:45 AM

• A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A LYSA Study from the Descar-T Registry Emmanuel Bachy

10:15 AM

• Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial , a Mantle Cell Lymphoma Network Study Marie-Hélène Delfau

12:45 PM

• The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy – Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma David Sibon

2:45 PM

• Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study Julien Lazarovici

 

 

Poster session 5:30 PM-7:30 PM

• Final Analysis of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA) Using Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Patients over 60 Years with Advanced-Stage Classical Hodgkin Lymphoma Hervé Ghesquières
• Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy Fabien Le Bras
• Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: SELINDA phase Ib LYSA Study  Marie Maerevoet

 

Sunday, Dec. 12th 2021

9:30 AM

• Rituximab-Lenalidomide(R2) maintenance is superior to rituximab maintenance after first Line Immunochemotherapy in Mantle Cell Lymphoma: results of the MCL R2 Elderly clinical trial par Vincent Ribrag

 

 

Poster session 6:00 PM-8:00 PM

• Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance Franck Morschhauser
• Single-cell and spatial analyses characterize distinct subsets of malignant T cells in angioimmunoblastic T cell lymphoma  François Lemonnier

 

 

Monday, Dec. 13th

10:45 AM

• Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study Krimo Bouabdallah

3:45 PM

• Kte-X19 in Relapsed or Refractory Mantle-CellLymphoma, a “Real-Life” Study from the Descar-T Registry and LYSA Group Charles Herbaux

5:30 PM

• Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell of Origin Classification of Mature T-cell Lymphoma Edith Julia

6:45 PM

• CAREL: Outcome of relapsed/refractory aggressive B-cell lymphoma patients relapsing after anti-CD19 CAR T-cells and enrolled in the DESCAR-T french national registry Roberta di Blasi

7:00 PM

• Total Metabolic Tumor Volume and Tumor Dissemination are independent prognostic factors in Advanced Hodgkin Lymphoma Salim Kanoun

 

Poster session 6:00 PM-8:00 PM

• A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the LYSA Amine Moslemi